p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses
Clinical & Translational Immunology ( IF 5.8 ) Pub Date : 2020-09-16 , DOI: 10.1002/cti2.1172
Lei Miao _{1,

2} , Xiao-Li Wei _{1,

3} , Qi Zhao ₁ , JingJing Qi ₁ , Chao Ren ₃ , Qi-Nian Wu _{1,

4} , Da-Liang Wei ₁ , Jia Liu ₁ , Feng-Hua Wang ₁ , Rui-Hua Xu _{1,

5}

Affiliation

Anti‐PD‐1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint‐responsive oesophageal squamous cell carcinoma (ESCC).

中文翻译：